299 related articles for article (PubMed ID: 28386990)
1. Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial.
Wysham C; Bonadonna RC; Aroda VR; Puig Domingo M; Kapitza C; Stager W; Yu C; Niemoeller E; Souhami E; Bergenstal RM;
Diabetes Obes Metab; 2017 Oct; 19(10):1408-1415. PubMed ID: 28386990
[TBL] [Abstract][Full Text] [Related]
2. Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents.
Davies MJ; Leiter LA; Guerci B; Grunberger G; Ampudia-Blasco FJ; Yu C; Stager W; Niemoeller E; Souhami E; Rosenstock J
Diabetes Obes Metab; 2017 Dec; 19(12):1798-1804. PubMed ID: 28432746
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial.
Aroda VR; Rosenstock J; Wysham C; Unger J; Bellido D; González-Gálvez G; Takami A; Guo H; Niemoeller E; Souhami E; Bergenstal RM;
Diabetes Care; 2016 Nov; 39(11):1972-1980. PubMed ID: 27650977
[TBL] [Abstract][Full Text] [Related]
4. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.
Rosenstock J; Aronson R; Grunberger G; Hanefeld M; Piatti P; Serusclat P; Cheng X; Zhou T; Niemoeller E; Souhami E; Davies M;
Diabetes Care; 2016 Nov; 39(11):2026-2035. PubMed ID: 27527848
[TBL] [Abstract][Full Text] [Related]
5. Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world.
Dailey G; Bajaj HS; Dex T; Groleau M; Stager W; Vinik A
BMJ Open Diabetes Res Care; 2019; 7(1):e000581. PubMed ID: 31114694
[TBL] [Abstract][Full Text] [Related]
6. More patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time-to-control analysis of LixiLan-O and LixiLan-L.
Frias J; Puig Domingo M; Meneghini L; Napoli R; Liu M; Soltes Rak E; Aroda VR
Diabetes Obes Metab; 2018 Sep; 20(9):2314-2318. PubMed ID: 29785837
[TBL] [Abstract][Full Text] [Related]
7. Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes.
Rosenstock J; Handelsman Y; Vidal J; Ampudia Blasco FJ; Giorgino F; Liu M; Perfetti R; Meier JJ
Diabetes Obes Metab; 2018 Dec; 20(12):2821-2829. PubMed ID: 29974618
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial.
Yang W; Dong X; Li Q; Cheng Z; Yuan G; Liu M; Xiao J; Gu S; Niemoeller E; Chen L; Ping L; Souhami E;
Diabetes Obes Metab; 2022 Aug; 24(8):1522-1533. PubMed ID: 35441412
[TBL] [Abstract][Full Text] [Related]
9. Benefits of the fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time-to-control analysis of the LixiLan JP phase 3 trials.
Terauchi Y; Yabe D; Kaneto H; Amano A; Baxter M; Watanabe D; Watada H; Inagaki N
Diabetes Obes Metab; 2020 Sep; 22 Suppl 4():35-47. PubMed ID: 33404200
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan-O randomized trial.
Davies MJ; Rosenstock J; Ali A; Russell-Jones D; Souhami E; Palmer K; Ji C; Niemoeller E; Skolnik N
Diabetes Obes Metab; 2022 Jan; 24(1):34-41. PubMed ID: 34617398
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial.
Watada H; Takami A; Spranger R; Amano A; Hashimoto Y; Niemoeller E
Diabetes Care; 2020 Jun; 43(6):1249-1257. PubMed ID: 32295808
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicentre study: The LixiLan JP-O2 randomized clinical trial.
Terauchi Y; Nakama T; Spranger R; Amano A; Inoue T; Niemoeller E
Diabetes Obes Metab; 2020 Sep; 22 Suppl 4():14-23. PubMed ID: 32291880
[TBL] [Abstract][Full Text] [Related]
13. Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial.
Davies MJ; Russell-Jones D; Barber TM; Lavalle-González FJ; Galstyan GR; Zhu D; Baxter M; Dessapt-Baradez C; McCrimmon RJ
Diabetes Obes Metab; 2019 Aug; 21(8):1967-1972. PubMed ID: 31124299
[TBL] [Abstract][Full Text] [Related]
14. Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial.
Blonde L; Bailey TS; Chao J; Dex TA; Frias JP; Meneghini LF; Roberts M; Aroda VR
Adv Ther; 2019 Sep; 36(9):2310-2326. PubMed ID: 31359368
[TBL] [Abstract][Full Text] [Related]
15. Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan-L-CN randomized controlled trial.
Yuan X; Guo X; Zhang J; Dong X; Lu Y; Pang W; Gu S; Niemoeller E; Ping L; Nian G; Souhami E;
Diabetes Obes Metab; 2022 Nov; 24(11):2182-2191. PubMed ID: 35762489
[TBL] [Abstract][Full Text] [Related]
16. Effects of age and disease duration on the efficacy and safety of iGlarLixi in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan-O-AP and LixiLan-L-CN trials.
Yang W; Guo X; Lauand F; Li L; Fang H; Du Q; Kang L
Diabetes Obes Metab; 2024 Apr; 26(4):1197-1206. PubMed ID: 38172083
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L randomized clinical trial.
Kaneto H; Takami A; Spranger R; Amano A; Watanabe D; Niemoeller E
Diabetes Obes Metab; 2020 Sep; 22 Suppl 4():3-13. PubMed ID: 32072742
[TBL] [Abstract][Full Text] [Related]
18. iGlarLixi, a titratable once-daily fixed-ratio combination of basal insulin and lixisenatide for intensifying type 2 diabetes management for patients inadequately controlled on basal insulin with or without oral agents.
Skolnik N; Dupree RS; Johnson EL
Curr Med Res Opin; 2017 Dec; 33(12):2187-2194. PubMed ID: 28741967
[TBL] [Abstract][Full Text] [Related]
19. Impact of dose capping in insulin glargine/lixisenatide fixed-ratio combination trials in patients with type 2 diabetes.
Schmider W; Belder R; Lee M; Niemoeller E; Souhami E; Frias JP
Curr Med Res Opin; 2019 Jun; 35(6):1081-1089. PubMed ID: 30550345
[TBL] [Abstract][Full Text] [Related]
20. Titratable fixed-ratio combination of insulin glargine plus lixisenatide: A simplified approach to glycemic control in type 2 diabetes mellitus.
Giorgino F; Caruso I; Napoli R
Diabetes Res Clin Pract; 2020 Dec; 170():108478. PubMed ID: 33002548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
